



Maine Department of Health and Human Services
MaineCare Services
Pharmacy Unit
11 State House Station
Augusta, Maine 04333-0011

PAUL R. LEPAGE
GOVERNOR

BETHANY L. HAMM
ACTING COMMISSIONER

To: MaineCare Providers
From: Jill Kingsbury, Director of Pharmacy
Date: September 26, 2018
Re: PDL Update for **09/28/2018**

The following medications have been recently added/changed to the MaineCare PDL as non-preferred and will require prior authorization.

Bonjesta Fulphila Kuvan Olumiant Retacrit Symtuza

The following medication has been recently added/changed to the MaineCare PDL as preferred and will *not* require prior authorization.

Prezcobix

The following medication have been recently added to the MaineCare PDL as well as new PDL criteria.

Jynarque is non-preferred and approvals will require clinical prior authorization for appropriate diagnosis. Concomitant use with strong CYP3A inhibitors is contraindicated. Avoid concomitant use of Jynarque® with OATP1B1/B3 and OAT3 substrates (e.g. statins, bosentan, glyburide, nateglinide, repaglinide, methotrexate, furosemide).

Lucemyra is non-preferred and approvals will require a clinical prior authorization for appropriate approved use and patient has documented contraindication to clonidine.

Palynziq is non-preferred and approvals will be for the treatment of patients \geq 18 years of age.

Tavalisse is non-preferred and is recommended for patients at risk of bleeding when one line of therapy (steroids, IVIG, splenectomy) has failed.

Aerobid Aers, Aerobid- M Aers and SSKI Sol are being removed from the PDL as they are no longer available.

If you have any questions, please contact Change Healthcare at 1-888-420-9711.